Video
Obesity Paradox in prostate cancer: potential explanations and next research steps
Author(s):
Video Player is loading.
Vinayak G. Wagaskar, MBBS, shares potential explanations for the “obesity paradox”—improved survival outcomes in patients with a high body mass index (BMI)—in patients with metastatic castration-resistant prostate cancer (mCRPC). A study presented at the 2021 European Association of Urology showed improved survival outcomes in obese patients with mCRPC compared with overweight and normal weight patients. In the video also discusses next steps with this research.
Wagaskar is an instructor of urology at Mount Sinai in New York City
Related Videos
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Related Content
